AVEO Pharmaceuticals (NASDAQ: AVEO) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare AVEO Pharmaceuticals to related businesses based on the strength of its valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership.
Institutional & Insider Ownership
51.0% of AVEO Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 4.7% of AVEO Pharmaceuticals shares are owned by company insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This table compares AVEO Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|AVEO Pharmaceuticals Competitors||-5,311.45%||-218.34%||-39.53%|
Risk & Volatility
AVEO Pharmaceuticals has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500. Comparatively, AVEO Pharmaceuticals’ competitors have a beta of 5.65, suggesting that their average share price is 465% more volatile than the S&P 500.
This is a summary of recent recommendations and price targets for AVEO Pharmaceuticals and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|AVEO Pharmaceuticals Competitors||863||3214||11668||232||2.71|
AVEO Pharmaceuticals currently has a consensus target price of $4.17, suggesting a potential upside of 40.29%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.12%. Given AVEO Pharmaceuticals’ competitors higher probable upside, analysts plainly believe AVEO Pharmaceuticals has less favorable growth aspects than its competitors.
Valuation & Earnings
This table compares AVEO Pharmaceuticals and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|AVEO Pharmaceuticals||$2.52 million||-$26.88 million||-4.18|
|AVEO Pharmaceuticals Competitors||$284.28 million||$33.78 million||81.33|
AVEO Pharmaceuticals’ competitors have higher revenue and earnings than AVEO Pharmaceuticals. AVEO Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
AVEO Pharmaceuticals competitors beat AVEO Pharmaceuticals on 8 of the 12 factors compared.
AVEO Pharmaceuticals Company Profile
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors. Tivozanib is designed to optimize VEGF blockade while minimizing off-target toxicities. Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity. Its preclinical studies suggest that neuregulin1 (NRG1) levels predict AV-203 antitumor activity in preclinical models. AV-380 is a humanized Immunoglobulin G 1 (IgG1) inhibitory monoclonal antibody. AV-380 targets growth differentiating factor 15 (GDF15).
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.